Positive PhIII can't salvage Merck's anacetrapib, now relegated to the scrap heap
There will be no CETP heart drug miracle in the works at Merck.
The pharma giant looked over a set of positive but troublesome Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
